Media stories about Celsion Corporation (NASDAQ:CLSN) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Celsion Corporation earned a news impact score of 0.12 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.9625896277919 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the media stories that may have impacted Accern Sentiment’s analysis:

A number of research firms have issued reports on CLSN. Zacks Investment Research downgraded shares of Celsion Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, October 17th. Maxim Group upgraded shares of Celsion Corporation from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a research report on Wednesday, October 4th. Finally, ValuEngine upgraded shares of Celsion Corporation from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $12.63.

Celsion Corporation (NASDAQ:CLSN) traded down 4.61% on Wednesday, reaching $2.07. 810,897 shares of the company’s stock were exchanged. Celsion Corporation has a 52 week low of $1.24 and a 52 week high of $15.26. The company’s market cap is $17.29 million. The stock’s 50 day moving average is $2.83 and its 200 day moving average is $1.80.

COPYRIGHT VIOLATION NOTICE: “Celsion Corporation (CLSN) Receives Daily Coverage Optimism Score of 0.12” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at

Celsion Corporation Company Profile

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).

Insider Buying and Selling by Quarter for Celsion Corporation (NASDAQ:CLSN)

Receive News & Stock Ratings for Celsion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corporation and related stocks with our FREE daily email newsletter.